Supraesophageal manifestations of gastroesophageal reflux disease.
An increasing amount of evidence indicates that gastroesophageal reflux disease (GERD) is a contributing factor to hoarseness, throat clearing, throat discomfort, chronic cough, and shortness of breath. The association between GERD and these supraesophageal symptoms may be elusive. Heartburn and regurgitation are absent in more than 50% of patients. Acid reflux should be considered if signs of GERD are present, symptoms are unexplained, or symptoms are refractory to therapy. The diagnosis of GERD may be unclear, despite a careful history and initial evaluation. A high index of suspicion is required to make the diagnosis. An empiric trial of antireflux therapy is appropriate when GERD is suspected. Multiprobe ambulatory pH monitoring is currently the diagnostic test of choice, but the level of sensitivity and specificity for supraesophageal manifestations of GERD is uncertain. Response to antireflux therapy is less predictable than typical GERD. More intensive acid suppression and longer treatment duration are usually required.
Al-Sabbagh
G
G
Division of Gastroenterology/Hepatology, University of Louisville School of Medicine, KY 40292, USA.
Wo
J M
JM
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D003371:Cough / Q000209:etiology; D004294:Domperidone / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000627:therapeutic use; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007818:Laryngeal Diseases / Q000209:etiology* / Q000503:physiopathology; D008991:Monitoring, Physiologic / Q000379:methods; D009853:Omeprazole / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D018492:Dopamine Antagonists; D004294:Domperidone; D009853:Omeprazole